Vyvanse and Miscarriage Risk
Based on the most recent high-quality evidence, Vyvanse (lisdexamfetamine) is associated with an increased risk of miscarriage, though the available data remains limited and the FDA label states that current evidence is "not sufficient to inform a drug-associated risk."
Current Evidence on Miscarriage Risk
The 2024 American Journal of Obstetrics and Gynecology guidelines note that lisdexamfetamine has limited published information regarding pregnancy outcomes 1. Since Vyvanse is a prodrug converted to dextroamphetamine, the risk profile should be extrapolated from amphetamine data 1.
Key Findings from Amphetamine Class Data:
- Amphetamines overall do not appear to be associated with major congenital malformations, including cardiac malformations 1
- The guidelines specifically state that amphetamines are not associated with "other significant adverse obstetrical or developmental outcomes" 1
- However, the FDA label explicitly states that available data on Vyvanse use in pregnancy are "not sufficient to inform a drug-associated risk for major birth defects and miscarriage" 2
Recent Research Evidence:
A 2025 Norwegian nationwide study provides the most concerning data: Among 13,298 pregnancies in women with ADHD, lisdexamfetamine exposure was associated with an adjusted odds ratio of 1.81 (95% CI 1.06-3.10) for miscarriage 3. This study found:
- Any ADHD medication use showed an adjusted OR of 1.60 (95% CI 1.41-1.83) for miscarriage 3
- Higher medication doses (measured by defined daily doses) showed a dose-response relationship, with the highest tertile showing an aOR of 2.11 (95% CI 1.71-2.60) 3
- Methylphenidate showed aOR 1.55, and atomoxetine showed aOR 2.34 3
Clinical Interpretation and Caveats
Important Limitations:
The Norwegian study has a critical methodological limitation: filled prescriptions may not reflect actual medication use during pregnancy 3. Many women may have discontinued medications upon learning of pregnancy, creating potential misclassification bias.
Confounding by indication is a major concern: Women with untreated ADHD have independently shown increased risks for spontaneous abortion and preterm birth 1. The observed association may reflect underlying ADHD severity rather than medication effect.
Mechanism of Potential Risk:
Amphetamines cause vasoconstriction that may decrease placental perfusion 2. Additionally, amphetamines can stimulate uterine contractions, potentially increasing risk of pregnancy loss 2.
Clinical Recommendations
Risk-Benefit Discussion:
When counseling patients, consider that:
- The absolute risk increase appears modest based on available data 3
- Untreated ADHD itself carries pregnancy risks including spontaneous abortion 1
- Non-pharmacological interventions (such as Dialectical Behavior Therapy modified for ADHD) should be considered as alternatives 1
- Alternative medications like bupropion or viloxazine may be considered, though pregnancy data are also limited 1
Monitoring Recommendations:
If Vyvanse is continued during pregnancy:
- Monitor for signs of decreased placental perfusion 2
- Be alert for premature labor given amphetamine's effect on uterine contractions 2
- Consider enrollment in the National Pregnancy Registry for Psychostimulants (1-866-961-2388) 2
Practical Approach:
For women planning pregnancy or in early pregnancy on Vyvanse, the decision should weigh:
- Severity of ADHD symptoms and functional impairment
- Response to non-pharmacological interventions
- The emerging but limited evidence suggesting increased miscarriage risk
- The known risks of untreated ADHD in pregnancy
In most cases, attempting a trial off medication or transitioning to non-pharmacological management during the first trimester would be the most cautious approach, given the 2025 Norwegian data showing dose-dependent miscarriage risk 3 and the FDA's acknowledgment of insufficient safety data 2.